Latest Triptans Stories
Researchers are developing a novel prochlorperazine nasal spray formulation as a potential new treatment for migraines. CHICAGO, Jan.
DURHAM, N.C., Jan. 13, 2015 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., today announced that it has completed a $37.1 million Series C preferred stock offering.
--Company Plans to Complete a New Human Factor Validation Study and Respond to the CRL in the First Half of Calendar 2015-- ALISO VIEJO, Calif., Nov.
Despite the Continued Launch of Generics, the Migraine Market Will Grow by over $2 Billion from 2013 to 2023, According to Findings from Decision Resources BURLINGTON, Mass., Nov.
ALISO VIEJO, Calif., Nov. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S.
ALISO VIEJO, Calif., Oct.
ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.
ALISO VIEJO, Calif., June 24, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the safety and efficacy of AVP-825, a Breath-Powered(TM)
MarketReportsOnline.com adds "Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-19)" report to its research store. Dallas, Texas (PRWEB)
AVP-825, Using OptiNose's Patented Bi-Directional(TM) Breath Powered(TM) Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.